Novo Holdings participates in USD 160m fundraising round
Novo Holdings, which is responsible for the Novo Nordisk Foundation’s investment activities, has participated in a funding round at American biotech company Obsidian Therapeutics, which deals with the treatment of solid tumors.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Holdings ramps up green investments
For subscribers